Rave New World: What Molly, Acid, DMT, and Edibles Actually Do Inside Your Brain

For each drug, this guide explains what someone may feel, why the brain changes, what can go wrong, and when to get help. It cannot tell you what is inside a pill, blotter, vape, chocolate, or gummy. That uncertainty is part of the risk.

A street name is not a laboratory result. “Molly” and “ecstasy” mean a product was sold as MDMA, not that MDMA is present. A logo, color, flavor, QR code, or trusted seller cannot establish identity, purity, strength, or what else was added.

The same is true of acid blotter, DMT vapes, cannabis edibles, and products sold as shroom bars. The package tells a story. The body encounters chemicals.

What matters most

• Timing is a safety issue. Delayed onset can lead someone to take more before the first amount has fully acted.
• The sought effect and the emergency can come from the same brain and body systems. Stimulation can become overheating; altered perception can become unsafe behavior.
• MAOIs are especially dangerous with MDMA, and ayahuasca contains MAO-A-inhibiting compounds. Never stop prescribed medicine to make a drug “work.”
• Reagent kits and fentanyl test strips can reduce some uncertainty but cannot prove purity, dose, potency, or safety.
• If someone will not wake, is breathing abnormally, has a seizure, collapses, is dangerously overheated, or loses contact with reality in a dangerous way, call 911.

Zoom

Fix the names before explaining the drugs

Drug checking in the United States has documented substitution, unexpected medicines, and mixed products. One analysis of 4,719 samples sold as MDMA and submitted to a drug-checking service from 1999 through 2023 identified 199 unique adulterants, and only about half of those samples contained MDMA alone.1 A separate analysis of 529 samples brought to DanceSafe from 2010 through 2015 produced a color reaction consistent with MDMA in about 60%.2

Neither figure is a national adulteration rate. People chose what to submit, markets changed across years and places, and color reagents cannot identify every compound or measure quantity. The studies establish possibility and variety, not the odds for a pill in one person’s hand.

Test technology answers narrow questions. A color change can be consistent with a chemical class while a second active remains invisible. A fentanyl strip can reduce one uncertainty while missing an analog, giving a false result, or saying nothing about stimulant potency. Laboratory methods can identify more, but a result belongs to the submitted sample, not every matching pill in a bag.

Uncertainty is not a reason to panic over every exposure. It is a reason to avoid promises. Symptoms, timing, co-use, prescribed medicines, and vital signs matter more in an emergency than confidence in a brand name.

Products sold as psychedelic chocolates or gummies create another layer of uncertainty. They may contain psilocybin, psilocin, a synthetic tryptamine, cannabinoids, Amanita-related compounds, an undisclosed medicine, several substances, or none of the expected drug. Shroom With a View examines that market in depth.

Risk is product, person, and place

The chemical is only one part of an emergency. Product identity and concentration may be unknown. The person may have heart disease, seizure history, bipolar disorder, psychosis vulnerability, pregnancy, dehydration, an infection, sleep deprivation, or prescribed medicines that change the response. The place may add heat, crowds, water, traffic, balconies, or no reliable friend.

This is why a person who “took the same thing” as friends can have a different outcome. They may not have received the same contents. Even if they did, metabolism, health, interactions, and setting differ. A prior uneventful exposure does not certify a later product or protect against an interaction.

Polysubstance use makes the causal picture harder and the emergency simpler. Alcohol can increase dehydration, vomiting, poor judgment, and aspiration risk. Stimulants can add cardiovascular and heat strain. Sedatives can hide agitation and then deepen unconsciousness. An unknown opioid can suppress breathing. Respond to the signs in front of you rather than waiting to identify a perfect cause.

Route and formulation change timing. Inhaled effects can appear quickly; swallowed products often have a longer delay. A liquid, powder, blotter, and food also differ in how evenly a chemical is distributed. These facts explain why symptoms may arrive at different times. They are not instructions for choosing or optimizing a route.

Health history is often unknown in a party setting. A person may not disclose lithium, an MAOI, heart disease, pregnancy, or a prior psychotic episode to friends. The safest emergency response does not require a confession. It requires calm observation, early help, and honest information to clinicians when available.

MDMA: a transporter surge with heat and water risks

MDMA, or midomafetamine, acts mainly by reversing and disrupting monoamine transporters. Serotonin transporter activity is prominent, with norepinephrine and dopamine transporters also involved. The result is a large change in serotonin, norepinephrine, and dopamine signaling. Oxytocin can increase and may contribute to social feelings, but it is not a proven single cause of empathy, trust, or closeness.3

When an oral product actually contains MDMA, effects often begin around 20 to 60 minutes and principal effects commonly last roughly three to six hours. Product contents, food, metabolism, co-use, and illness can shift that timeline. This range is here to explain why toxicity may be delayed, not to guide redosing.

People may report warmth, energy, closeness, sensory intensity, and reduced social fear. Unwanted effects can include jaw tension, nausea, sweating, anxiety, panic, rapid heart rate, high blood pressure, confusion, and impaired judgment.

The most dangerous progression can involve severe hyperthermia, agitation, rigidity, seizures, arrhythmia, liver injury, kidney injury, or serotonin toxicity. Exertion in a crowded hot environment raises heat risk. Dehydration is dangerous, but so is excessive water. MDMA can contribute to water retention, and drinking too much plain water can dilute blood sodium. Hyponatremia may cause severe headache, vomiting, confusion, seizure, brain swelling, or death.4

Heat illness and low sodium can overlap in confusion, vomiting, or seizure, and a bystander cannot safely distinguish them by guesswork. That is why “cool them down” or “give water” is not a complete response. Move away from heat if it can be done safely, call 911, follow the dispatcher, and do not force anything by mouth into an impaired person. Emergency clinicians can measure temperature, sodium, organ injury, and cardiac rhythm.

Serotonin toxicity is also a clinical pattern rather than a feeling of being “too high.” Agitation, confusion, sweating, high temperature, muscle rigidity, clonus or uncontrolled shaking, diarrhea, and unstable vital signs can appear in different combinations. The risk rises with interacting serotonergic drugs, but a bystander should use the same emergency threshold regardless of which combination is suspected.

Aftereffects can include poor sleep, fatigue, low mood, anxiety, and concentration difficulty. The popular phrase “Tuesday blues” is not proof that one experience permanently depleted serotonin. Sleep loss, exertion, expectations, other drugs, dose uncertainty, and individual vulnerability all contribute.

Persistent low mood deserves direct attention, especially after little sleep or in someone with depression or bipolar vulnerability. Suicidal thinking, inability to care for oneself, psychosis, or manic symptoms are not a routine comedown to wait out alone. Call or text 988 in the United States for a suicidal or mental-health crisis, and call 911 for immediate danger.

Jaw tension, sweating, and stimulation may appear common enough to normalize, but severity and clustering matter. Increasing confusion, very high temperature, rigidity, severe headache, repeated vomiting, or collapse changes the situation from observation to emergency response.

MDMA and psychiatric medicines

Controlled studies often find that SSRIs or SNRIs attenuate subjective and physiologic MDMA effects. That does not make a combination safe or predictable. Monoamine oxidase inhibitors have the clearest severe danger because combining strong monoamine release with impaired breakdown can produce life-threatening toxicity. A forensic series described four deaths after people took a monoamine oxidase inhibitor together with MDMA, apparently in an attempt to intensify the drug.5 Multiple serotonergic or stimulating substances add uncertainty.6

Do not stop an antidepressant to intensify MDMA. Abrupt discontinuation can cause withdrawal, relapse, suicidal symptoms, mania, or other harm. No article can provide a safe washout period for an unknown product.

Clinical research does not validate a rave product

In August 2024, FDA issued a complete response letter for the MDMA-assisted-therapy application for PTSD and asked the sponsor to conduct an additional Phase 3 trial.78 In August 2026, MAPS confirmed that the renamed sponsor, Resilient Pharmaceuticals, had resubmitted the application without a new Phase 3 study.9 FDA had not publicly announced acceptance of that resubmission or a target action date, and a resubmission is not acceptance or approval. Midomafetamine remained investigational and was not FDA approved for PTSD or another condition on September 3, 2026.

A clinical trial uses a known product, screening, preparation, protocolized psychotherapy, vital-sign monitoring, adverse-event collection, and follow-up. Those safeguards do not transfer to a capsule sold as Molly.

LSD: a long experience with no label guarantee

LSD is a classic psychedelic whose effects are strongly linked to serotonin 5-HT2A receptor activity, with other receptor actions also contributing.10 When the substance is actually LSD, effects often begin within about 30 to 90 minutes and commonly last roughly seven to 11 hours, sometimes longer.1112 Individual and product variation is substantial.

Visual patterning, altered time, intensified emotion, unusual meaning, and changes in the sense of self may occur. So can panic, paranoia, disorganization, vomiting, unsafe wandering, traffic injury, falls, or dangerous decisions. A long duration can turn early distress into an exhausting crisis.

LSD has low classic physical-dependence potential and no recognized typical withdrawal syndrome. That does not make it safe. Mania or psychosis can emerge or worsen in vulnerable people. Some people report persistent visual phenomena, called hallucinogen persisting perception disorder, or HPPD. The condition appears uncommon, definitions vary, and reliable incidence is not known.10

Set and setting affect distress, but they are not armor. A calm room does not remove cardiovascular illness, an unexpected substitute, or psychiatric vulnerability. A frightening experience does not automatically mean permanent psychiatric illness, either. Persistent insomnia, paranoia, hallucinations, unusual certainty, or major functional change after the acute period deserves assessment, especially when there is a personal or family history of bipolar or psychotic illness.

The long duration changes supervision needs. A friend who seems physically stable but remains profoundly disoriented can wander, misread traffic, climb, enter water, or react defensively. Reduce stimulation, speak simply, avoid arguing about perceptions, remove immediate hazards, and seek emergency help for danger, severe agitation, chest or breathing symptoms, seizure, or collapse.

A blotter sold as LSD can contain an NBOMe compound or another potent chemical. NBOMes have caused severe agitation, seizures, hyperthermia, cardiovascular toxicity, and deaths.13 Appearance and bitter taste are not reliable identification systems, and this article does not provide a test for deciding that a blotter is safe.

Physical dependence is only one dimension of harm. An infrequently used drug can still produce a catastrophic accident, a prolonged psychiatric episode, or a toxic-substitute exposure. Conversely, an intense and frightening state may resolve with appropriate support and not become permanent illness. The role of emergency care is to protect the person while that uncertainty is assessed.

DMT and ayahuasca: the route changes the clock

DMT is another serotonergic psychedelic with important 5-HT2A activity and other targets. When inhaled, effects can start within moments and become intensely disorienting. Controlled evidence shows effects peaking around five minutes, with inhaled experiences commonly resolving within about 5 to 20 minutes and intravenous studies showing full return to baseline by roughly 12 to 30 minutes.14 The course is brief, but it is not a fixed five-minute event.

Brief does not mean mild. Loss of environmental awareness, panic, falls, burns, traffic exposure, blood-pressure or heart-rate changes, and psychiatric destabilization can occur. A vape sold as DMT may contain an unknown concentration or another chemical.

Ayahuasca is not simply long-acting inhaled DMT. It is a variable plant preparation combining DMT-containing material with beta-carbolines that reversibly inhibit monoamine oxidase A. That inhibition makes oral DMT active and creates effects lasting several hours, with wide ceremonial and product variation.14

MAO-A inhibition also creates interaction risk with serotonergic, stimulant, and other monoaminergic medicines. Vomiting is common in some settings but should not be romanticized as cleansing. Persistent vomiting, confusion, chest symptoms, extreme agitation, severe headache, seizure, or collapse needs medical attention. Never change prescribed medication for a ceremony without the prescriber.

“Natural” does not settle safety. Plant species, preparation, added ingredients, storage, and facilitator practices vary. A ceremonial setting may provide community or structure, but it is not automatically a licensed medical environment. Screening can miss undisclosed illness or medication. Remote location can delay emergency care. None of this is a judgment about spiritual practice; it is the difference between cultural meaning and verified medical capacity.

Cannabis edibles: the delayed clock

THC acts mainly at cannabinoid receptors, especially CB1 receptors in the brain. After oral use, the liver converts some THC to active 11-hydroxy-THC. Effects are delayed and can feel different from inhaled cannabis.

CDC notes that edible effects may take 30 minutes to two hours to begin.15 Peak and offset can come much later, and impairment may continue into the next day. The common hazard is impatience: someone assumes nothing happened and takes more before the first exposure has fully acted.

Acute problems include panic, paranoia, vomiting, severe drowsiness, confusion, impaired driving, falls, abnormal heart rate, and accidental child ingestion. Gummies look like ordinary candy. Child-resistant packaging and locked storage matter even when adults know what a product is.

Products labeled delta-8 THC add regulatory and manufacturing uncertainty. FDA has not evaluated or approved delta-8 THC products for safe use, and conversion from hemp-derived cannabinoids may create contaminants or variable byproducts.16 Federal law also changed in November 2025 to define hemp by total THC and to cap finished products at 0.4 mg of total THC per container, excluding cannabinoids synthesized outside the plant. That change takes effect on November 12, 2026 and is expected to remove most intoxicating hemp products from legal sale.17 “Hemp” does not mean non-intoxicating, and a gas-station or online package is not a dosing certificate.

If someone becomes anxious but remains awake, breathing normally, and physically safe, reduce noise and stimulation, keep a calm person present, and avoid driving. Chest symptoms, fainting, severe confusion, repeated vomiting, dangerous behavior, or a child exposure crosses into medical or Poison Control guidance. Do not rely on sleep as a safety test when the substance is uncertain.

Cannabis hyperemesis syndrome is a pattern of recurrent nausea, vomiting, and abdominal pain most often associated with prolonged, frequent exposure. It should not be used as a label for every one-time episode of vomiting after an edible.

Driving impairment can outlast the most obvious intoxication. Feeling less altered is not proof of restored reaction time, attention, or judgment. A planned ride should not become a backup driver who also used cannabis, alcohol, or another substance.

For a child, drowsiness, abnormal behavior, poor coordination, vomiting, or breathing change after possible edible exposure deserves immediate expert guidance. Do not wait for the child to confirm what happened, and do not induce vomiting unless instructed.

Cannabis and psychosis risk

In an 11-site European and Brazilian case-control study published in 2019, involving 901 people with first-episode psychosis and 1,237 controls, daily cannabis use was associated with higher odds of psychotic disorder than never use, adjusted odds ratio 3.2, 95% CI 2.2 to 4.1. Daily use of high-potency cannabis, defined as THC of 10 percent or more, had an adjusted odds ratio of 4.8, 95% CI 2.5 to 6.3.18

This was observational. It cannot prove that cannabis caused an individual episode, and potency, selection, shared vulnerability, and reverse causation complicate interpretation. It does support extra caution with frequent, high-potency exposure and personal or family vulnerability to psychosis.

Products sold as psilocybin edibles

If psilocybin is present, the body converts it to psilocin. Packaging cannot establish that it is present.

The Diamond Shruumz outbreak made that uncertainty visible. The final 2026 CDC report identified 180 cases of moderate or major illness in 34 states, with 73 hospitalizations, 38 ICU admissions, 29 intubations, and two associated deaths.19 Reported effects included seizures, loss of consciousness, abnormal heart rate or blood pressure, nausea, vomiting, agitation, and confusion.

FDA testing of different batches detected varying combinations, including muscimol, psilocin, acetylpsilocin, kavalactones, and pregabalin. Not every substance was in every product. The investigation could not assign every illness or associated death to one ingredient. The lesson is not that one detected chemical explains the outbreak. It is that a branded food-like product can contain an unstable mixture that consumers cannot verify.

The outbreak also shows why a recall date matters. A photo of old packaging can help an investigator, but similar packaging may be reused by unrelated sellers. A QR code may lead to a document that was not generated from the item in hand. Even a real laboratory certificate can describe a submitted sample rather than every unit in a production run. Clinical decisions should be based on symptoms and possible exposure, not confidence in the wrapper.

A companion article covers mushrooms, cultivar names, retail testing, clinical research, long-term claims, and law: Shroom With a View.

Comparison: labels, timelines, and emergencies

Why younger brains and lives can face different risks

Brain maturation continues well past the teenage years, but no single birthday marks a finish line, and age 25 is not a magic cutoff. Adolescence and young adulthood also bring more experimentation, sleep loss, driving risk, unfamiliar settings, peer pressure, and mixing. These social and developmental factors can matter as much as a receptor claim.

The same age period overlaps with common onset of bipolar and psychotic disorders. That overlap does not prove a drug caused an episode. A substance can still trigger, unmask, or worsen symptoms in a vulnerable person, and an emergency cannot wait for the causal debate.

Cannabis has specific observational evidence linking frequent and high-potency use with psychosis risk. Psychedelic-specific developmental evidence is much thinner. Do not transfer cannabis estimates to LSD, DMT, MDMA, or psilocybin, and do not tell a young person that one exposure permanently rewired the brain.

Risk conversations work better when they are concrete. “Your brain is not developed” can sound dismissive and scientifically absolute. “This is the age when sleep loss, unfamiliar products, driving, and first mood or psychotic episodes often collide” gives a young person information they can recognize.

Parents also need room for uncertainty. Sudden withdrawal, sleeplessness, paranoia, or agitation could reflect a substance, a first psychiatric episode, a medical illness, or several at once. Safety and assessment come before proving which explanation is morally correct.

Honest survival: limits, not a safety guarantee

Avoiding use is the only way to eliminate drug-specific risk. Unknown drugs, alcohol, prescribed medicines, and other substances can combine unpredictably. No test or plan makes an unknown product safe.

• Do not stop prescribed medication to take a party drug. MAOIs are especially dangerous with MDMA, and ayahuasca itself contains MAO-A-inhibiting compounds.
• Stay with a person who is impaired. Keep them away from driving, swimming, heights, traffic, and extreme heat.
• Hydration must be moderate. Dehydration and excessive water can both be dangerous. Never force fluids into someone who is confused, seizing, vomiting, or unconscious.
• Reagent kits are presumptive. They cannot establish purity, dose, potency, or absence of every contaminant.
• Fentanyl test strips have limits. They can give false results, may miss analogs, and cannot prove safety.
• Call 911 immediately. If opioid exposure is possible, give naloxone according to its instructions as soon as you can; if you are alone, give naloxone first and then call. Follow dispatcher directions for rescue breathing or CPR, place the person on their side if they are breathing and it is safe, and stay until help arrives. Improvement after naloxone does not cancel the emergency response.
• Naloxone helps only if someone already has it. SAMHSA publishes a plain-language overdose response toolkit, and California distributes free naloxone and fentanyl test strips through the state Naloxone Distribution Project.2021

California Health and Safety Code section 11376.5 gives limited protection for specified under-the-influence, personal-use possession, and paraphernalia offenses when someone seeks medical help in good faith for an overdose and does not obstruct medical or law enforcement personnel. It covers both the person who calls for help and the person experiencing the overdose. It is not blanket immunity and does not cover sales, furnishing, impaired driving, warrants, or unrelated offenses.22 Call for help. Do not promise anyone that every legal consequence disappears.

When calling 911, give the location first. Say what the person is doing: “not waking and breathing slowly,” “seizing,” or “very hot and confused.” Share every possible substance, prescribed medicine, time, package, and route you know. Honest information helps clinicians treat temperature, sodium, heart rhythm, breathing, or serotonin toxicity. You do not need to solve the diagnosis before the ambulance arrives.

Do not make an impaired person walk, shower alone, or “sleep it off.” Do not put them in a cold bath, restrain them face down, or force vomiting. If breathing stops and the dispatcher instructs CPR or rescue breathing, follow those instructions. Keep wrappers or remaining material away from children and bring them for professionals if doing so is safe.

If several people used the same product, one person’s emergency is a warning for the others. Stop further exposure, keep the remaining material away from anyone else, and tell responders who may have taken it. People without symptoms may still need Poison Control advice because onset can be delayed.

An emergency department is not a punishment. Clinicians may need to monitor temperature, sodium, kidney and liver injury, heart rhythm, glucose, and breathing. A person can look calmer while a dangerous abnormality continues. Leaving because the frightening behavior eased can miss delayed complications.

After the immediate danger, follow-up can address sleep, mood, trauma from the event, substance-use patterns, and what friends witnessed. Persistent paranoia, perceptual disturbance, depression, or mania deserves clinical care. Survival is not the end of the health question.

A calm, factual debrief can also improve the next emergency response. Review when people noticed danger, who called, where naloxone was kept, whether the location was clear, and which assumptions caused delay. This is safety learning, not a promise that future use can be made safe.

The lesson should remain available without blame or spectacle.

Call 911 now for these signs

• Inability to wake, slow or abnormal breathing, or blue or gray lips.
• Seizure, collapse, severe chest pain, or severe breathing trouble.
• Very hot skin, high temperature, severe agitation, rigidity, confusion, or uncontrolled shaking.
• Severe headache, repeated vomiting, confusion, or seizure after a product sold as MDMA.
• Dangerous loss of contact with reality, violent or unsafe behavior, or suicidal behavior.
• Significant symptoms in a child after an edible or unknown product.

For an uncertain but not immediately life-threatening U.S. exposure, call Poison Control at 1-800-222-1222. Do not leave the person alone while seeking guidance.23

For a psychiatric or behavioral crisis rather than a poisoning, a local 24-hour mobile crisis team can respond:

• Riverside County mobile crisis response: 951-686-HELP (951-686-4357).
• San Bernardino County Community Crisis Response Team: 800-398-0018.

What a Parent Can Say in 30 Seconds

“I want to understand what you are seeing, not trap you into a confession. My safety rule is that you never ride with an impaired driver and you call 911 if someone will not wake, has a seizure, cannot breathe normally, or is dangerously overheated. Call me anytime for a ride. We can deal with the rest after everyone is safe.”

Frequently asked questions

Are Molly and ecstasy always MDMA?

No. They are market labels. A product may contain MDMA, another stimulant, a mixture, or something else. Packaging and seller claims cannot verify it.

Can a test kit prove a pill is safe?

No. A reagent may suggest that a chemical class is present. It cannot prove purity, amount, potency, or absence of all contaminants. Fentanyl strips also have false-result and analog limits.

Can MDMA and an antidepressant be mixed?

Interactions are unpredictable. SSRIs and SNRIs often blunt MDMA effects in controlled studies, while MAOIs create an especially serious danger. Never stop an antidepressant for MDMA; ask the prescriber about any exposure.

Why can too much water be dangerous at a rave?

MDMA can promote water retention. Excessive plain water can dilute sodium, causing headache, vomiting, confusion, seizure, brain swelling, or death. Hydration should be moderate, and fluids should never be forced into an impaired person.

What should I do if my friend will not wake up?

Call 911 immediately. If opioid exposure is possible, give naloxone according to its instructions as soon as you can; if you are alone, give naloxone first and then call. Follow dispatcher directions for rescue breathing or CPR, place the person on their side if they are breathing and it is safe, and stay until help arrives. Improvement after naloxone does not cancel the emergency response.

Recognition beats spectacle

The most useful knowledge is not a colorful description of a high. It is what a label cannot tell you, which warning signs matter, and how quickly to call. If the product is a mushroom, chocolate, or gummy, Shroom With a View explains the additional identity, trial, and legal questions.

This article is education and emergency recognition, not a use guide or legal advice. It does not provide doses, combinations, redosing intervals, sourcing, medication washouts, or a way to certify an unknown product as safe.

Related reading on NP FADY

• Shroom With a View: Strains, Chocolate Bars, and What Psilocybin Really Does to Your Brain, Now and Years Later
• Cannabis and Mental Health

References

1. Sevigny EL, Thyssen S, Erowid E, Lea R. Misrepresentation of MDMA in the United States, 1999-2023. Drug Alcohol Depend. 2024;264:112467. https://pubmed.ncbi.nlm.nih.gov/39437494/

2. Saleemi S, Pennybaker SJ, Wooldridge M, Johnson MW. Who is ‘Molly’? MDMA adulterants by product name and the impact of harm-reduction services at raves. J Psychopharmacol. 2017;31(8):1056-1060. https://journals.sagepub.com/doi/abs/10.1177/0269881117715596

3. Kuypers KPC, de la Torre R, Farre M, Yubero-Lahoz S, Dziobek I, Van den Bos W, Ramaekers JG. No evidence that MDMA-induced enhancement of emotional empathy is related to peripheral oxytocin levels or 5-HT1a receptor activation. PLOS One. 2014;9(6):e100719. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0100719

4. National Library of Medicine. 3,4-Methylenedioxymethamphetamine (MDMA) Toxicity. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK538482/

5. Vuori E, Henry JA, Ojanpera I, et al. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction. 2003;98(3):365-368. https://pubmed.ncbi.nlm.nih.gov/12603236/

6. Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology (Berl). 2022;239(6):1945-1976. https://pmc.ncbi.nlm.nih.gov/articles/PMC9177763/

7. U.S. Food and Drug Administration. Psychopharmacologic Drugs Advisory Committee meeting, NDA 215455, midomafetamine capsules. June 4, 2024. https://www.fda.gov/media/180703/download

8. Lykos Therapeutics. Lykos Therapeutics Announces Complete Response Letter for Midomafetamine Capsules for PTSD. August 9, 2024. https://www.prnewswire.com/news-releases/lykos-therapeutics-announces-complete-response-letter-for-midomafetamine-capsules-for-ptsd-302219182.html

9. Multidisciplinary Association for Psychedelic Studies. MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA. August 10, 2026. https://maps.org/2026/08/10/maps-responds-to-report-of-progress-for-mdma-assisted-therapy-for-ptsd-with-fda/

10. National Institute on Drug Abuse. Psychedelic and Dissociative Drugs. https://nida.nih.gov/research-topics/psychedelic-dissociative-drugs

11. National Library of Medicine. LSD toxicity. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK482407/

12. Holze F, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2021. https://www.nature.com/articles/s41386-020-00883-6

13. Suzuki J, Dekker MA, Valenti ES, et al. Toxicities associated with NBOMe ingestion, a novel class of potent hallucinogens: a review of the literature. Psychosomatics. 2015;56(2):129-139. https://pmc.ncbi.nlm.nih.gov/articles/PMC4355190/

14. Egger K, Aicher HD, Cumming P, Scheidegger M. Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors. Cell Mol Life Sci. 2024;81(1):395. https://pmc.ncbi.nlm.nih.gov/articles/PMC11387584/

15. Centers for Disease Control and Prevention. Cannabis and Poisoning. https://www.cdc.gov/cannabis/health-effects/poisoning.html

16. U.S. Food and Drug Administration. 5 Things to Know about Delta-8 Tetrahydrocannabinol. https://www.fda.gov/consumers/consumer-updates/5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc

17. Arnold & Porter. Continuing Resolution Introduces Major Changes to Federal Regulation of Hemp-Derived Products. December 2025. https://www.arnoldporter.com/en/perspectives/advisories/2025/12/major-changes-to-federal-regulation-of-hemp-derived-products

18. Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427-436. https://pubmed.ncbi.nlm.nih.gov/30902669/

19. Rumph JT, et al. Severe Illness Associated with Eating Mushroom-Containing Chocolate Products, United States, January-October 2024. MMWR Morb Mortal Wkly Rep. 2026;75(13). https://www.cdc.gov/mmwr/volumes/75/wr/mm7513a2.htm

20. Substance Abuse and Mental Health Services Administration. Overdose Prevention and Response Toolkit. PEP23-03-00-001. https://library.samhsa.gov/product/overdose-prevention-response-toolkit/pep23-03-00-001

21. California Department of Health Care Services. Naloxone Distribution Project. https://www.dhcs.ca.gov/individuals/naloxone-distribution-project/

22. California Legislature. Health and Safety Code section 11376.5. https://leginfo.legislature.ca.gov/faces/codes_displaySection.xhtml?lawCode=HSC&sectionNum=11376.5

23. America’s Poison Centers. Get Poison Help. https://poisoncenters.org/

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.